Phesgo
HER2+ Breast Cancer
ApprovedCommercial
Key Facts
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. is Japan's premier biotechnology company and a subsidiary of Roche, focusing on precision medicine and innovative drug development. Founded in 1925, the company has built a strong portfolio in oncology, autoimmune diseases, and rare conditions through both in-house R&D and strategic partnerships with Roche. Chugai operates as Roche's key development and commercialization hub in Japan while maintaining its independent research capabilities and Tokyo Stock Exchange listing.
View full company profileTherapeutic Areas
Other HER2+ Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Kadcyla (T-DM1) | Chugai Pharmaceutical | Approved |
| HS-10504 | Hansoh Pharma | Phase 1 |
| Trastuzumab Biosimilar | Hansoh Pharma | Approved |